Molina Healthcare reported a significant miss for Q4 and FY 2025, with Q4 adjusted EPS of negative $2.75 and full-year EPS of $11.03, falling well short of the initial $24.50 guidance due to unprecedented medical cost trends of 7.5% and retroactive rate actions in California. Despite the top-line growth of 11% to $43.1 billion in revenue, pretax margins compressed to 1.6%. Management characterized 2025 as a 'tale of 2 halves,' with the second half severely impacted by acuity shifts from redeterminations and elevated utilization in Medicare and Marketplace. For 2026, the company issued conservative guidance of at least $5.00 EPS on approximately $42 billion in revenue, reflecting a 'trough' margin environment in Medicaid (1.2% pretax margin) and strategic exits from volatile segments. However, management highlighted strong strategic wins, including a $6 billion Florida CMS contract, and emphasized that 'intrinsic value remains unchanged' with over $11 per share in embedded earnings, anticipating a return to rate equilibrium.
| Metric | Value | Change |
|---|---|---|
| Q4 Premium Revenue | $10.7 billion | N/A |
| FY 2025 Premium Revenue | $43.1 billion | +11% |
| Q4 Adjusted EPS | -$2.75 | Miss |
| FY 2025 Adjusted EPS | $11.03 | vs $24.50 initial guide |
| FY 2025 Pretax Margin | 1.6% | Below target |
| FY 2025 Medicaid MCR | 91.8% | N/A |
| FY 2025 Medicare MCR | 92.4% | N/A |
| FY 2025 Marketplace MCR | 90.6% | N/A |
| 2026 EPS Guidance | At least $5.00 | Down from 2025 |
| 2026 Premium Guidance | ~$42 billion | -2.3% |
| Embedded Earnings | >$11/share | N/A |
Molina is executing a major strategic pivot in its Medicare segment by deciding to exit the traditional MAPD product in 2027. Management stated that the MAPD product 'does not align with our strategic shift to focus exclusively on dual eligible members.' This move is expected to remove a drag on earnings (estimated at $1 per share in 2026) and allows the company to redeploy capital toward its 'integrated' products designed for dual-eligibles, which they believe offer better long-term margin potential and alignment with their clinical capabilities.
The company secured a landmark win in Florida, securing the sole Children's Medical Services (CMS) contract. This contract is expected to generate $6 billion in annual run-rate premium when it goes live in late 2026. Management emphasized that despite the initial start-up costs and higher Medical Cost Ratios (MCRs) typical of new business, this win adds $4.50 to their 'embedded earnings' per share and significantly bolsters their Medicaid footprint, reinforcing their dominance in high-acuity Medicaid populations.
Management is aggressively de-risking the Marketplace segment by reducing exposure. They increased pricing by an average of 30% (ranging from 15% to 45%) and reduced their footprint by 20%. This strategic retreat is designed to 'stabilize margins in this highly volatile risk pool.' Consequently, they expect Marketplace membership to drop by over 50% and premium revenue to decline by $2.3 billion, prioritizing profitability over revenue in this segment.
Molina is actively pursuing M&A to capitalize on the distressed operating environment. CEO Joe Zubretsky noted that the current rate/trend imbalance is a 'catalyst for many smaller and less diverse health plans to consider their strategic options.' Management stated they are looking to acquire revenue at 'book value' or 'just over 20% of revenue,' contrasting with previous cycles, to build long-dated revenue streams that can be managed to target margins within 2-3 years.
The company highlighted a massive 'embedded earnings' pipeline exceeding $11 per share. This figure represents future contract revenue at target margins that has been won but not yet realized (e.g., Florida CMS, Georgia, Texas). Management views this as a key driver of future growth, arguing that once the current 'rate restoration' cycle occurs, these embedded earnings will layer on top of the legacy business, driving significant EPS expansion.
The 2025 financial performance was a catastrophic miss relative to guidance. Initial EPS guidance was $24.50, but actual results were $11.03—a shortfall of over 50%. Management attributed nearly half of this to 'unprecedented trend' in the Marketplace segment, which represents only 10% of premium, indicating a severe failure in underwriting or pricing assumptions within that specific business line.
Medical cost trends remain highly elevated and unpredictable. Management reported a 7.5% trend in 2025, driven heavily by behavioral health (18% service trend), pharmacy (13%), and professional office visits (16%). While they project a moderation to 5% in 2026, this assumption relies on the belief that the redetermination-related acuity shift (250 bps) was a one-time event. If utilization remains elevated, margins could compress further.
The California Medicaid segment presented a specific and unexpected risk with $2 per share of retroactive hits due to 'unforeseen state actions.' This included a retroactive risk corridor for the undocumented population and a risk adjustment update in LA County. The fact that these were 'event-driven' and 'new and unforeseen' highlights the regulatory and political risks inherent in Molina’s Medicaid-heavy portfolio.
The 2026 guidance implies a massive earnings contraction, with EPS dropping to at least $5.00 from $11.03 in 2025. Management explicitly burdened this guidance with $1.50 for the Florida contract start-up and $1.00 for the underperforming MAPD product. While they frame this as a 'trough,' the step-down in earnings power is severe and raises questions about the company's ability to grow earnings in the near term.
Marketplace volatility remains a concern, with the Q4 MCR hitting 99%. Management noted 'elevated utilization across nearly all services' and 'prior period provider claim settlements.' The decision to drastically shrink this business suggests that management does not believe they can accurately price or manage the risk pool in the current subsidy environment, effectively admitting defeat in this line of business for the foreseeable future.
Overall: Management displayed a tone of resilient confidence and transparency. While CEO Joe Zubretsky was candid and apologetic about the 2025 performance, admitting it was 'clearly a tale of 2 halves' and an 'aberration,' he quickly pivoted to a defense of the company's long-term structural advantages. The demeanor shifted from acknowledging the 'disappointing' short-term results to aggressively promoting the 'durable and sustainable operating platform' and the 'intrinsic value' of the firm. There was no panic; instead, there was a heavy reliance on data regarding 'embedded earnings' and 'actuarial soundness' to reassure investors.
Confidence: HIGH - Management maintained high confidence in the long-term thesis despite the near-term miss. They framed the 2026 guidance as a definitive 'trough' with 'significant upside' through rate restoration. The specificity of their 'embedded earnings' ($11+) and the detailed defense of their 5% trend assumption suggests strong conviction in their modeling, even as they acknowledged the difficulty of the current environment.
At least $5.00
Approximately $42 billion
92.9%
94.0%
85.5%
1.2%
30%
Hedging & Uncertainty: Management used specific temporal and probabilistic hedges to frame the 2025 miss as temporary. They repeatedly used terms like 'aberration,' 'anomaly,' and 'tale of 2 halves' to isolate the poor performance to a specific period rather than a systemic failure. Phrases like 'we believe,' 'we expect,' and 'projected' were used frequently regarding the 2026 recovery, particularly around 'actuarial soundness prevailing.' However, they hedged the 2026 guidance by stating it is 'at least $5,' creating a floor while leaving upside open. They also used defensive hedging regarding the trend, stating 'we didn't soften any of what we experienced in '25' to justify their 5% assumption.
2025 was clearly a tale of 2 halves... Trend pressure work against us in each of the third and fourth quarters. - Joseph Zubretsky, CEO
We believe the medical cost trend in 2025 was an aberration, an anomaly by historical standards. - Joseph Zubretsky, CEO
The intrinsic value of our businesses remains unchanged. - Joseph Zubretsky, CEO
We believe our 2026 forecast for Medicaid is the trough for managed Medicaid margins. - Joseph Zubretsky, CEO
We anticipate that actuarial soundness will ultimately prevail as Medicaid rates are restored by state actuarial processes. - Joseph Zubretsky, CEO
This is the perfect environment to be exploring M&A... give me a property at book value, and I'm good to go. - Joseph Zubretsky, CEO
We have determined that the MAPD product does not align with our strategic shift... and we will exit the traditional MAPD product for 2027. - Joseph Zubretsky, CEO
Analyst Sentiment: Analysts were highly skeptical and pressed management aggressively on the reliability of the 2026 guidance, specifically the 5% trend assumption and the 'trough' narrative. Questions focused heavily on the disconnect between the 7.5% trend experienced in 2025 and the projected moderation, with analysts seeking more concrete evidence than just 'mean reversion.' There was also significant focus on the sustainability of the Florida CMS contract margins and the mechanics of the California retroactive adjustments.
Management Responses: Management responses were data-heavy and defensive, utilizing granular 'cohort analysis' to explain away the trend as a function of 'low and no users' leaving the system during redeterminations. They stood firm on the 5% trend number, arguing it was 'fully loaded' with current inflationary pressures. They effectively used the 'embedded earnings' concept to shift the conversation from current earnings to future potential, and they were transparent about the 'drag' from new business starts, framing them as investments rather than permanent losses.
Medicaid Trend & Acuity Shift: Analysts questioned the 250 basis point impact of redeterminations and whether it was truly a one-time event. Management argued that the 'low users' have largely left the system, stabilizing the acuity mix going forward.
California Retroactive Items: There was deep interest in the specific mechanics of the $2/share charge in California. Management clarified that this was due to a unique state-funded corridor for undocumented immigrants and a risk adjustment refresh, which they do not expect to replicate elsewhere but have pulled through into 2026 assumptions.
Marketplace Pricing & Retention: Analysts probed the 30% price increases and retention assumptions. Management admitted that 'effectuation' is lower (60%) and that they expect significant attrition through the grace period as members see the new, higher premiums.
Florida CMS Contract: Questions focused on the start-up costs and the $1.50 drag. Management clarified that this includes pre-revenue hiring and reserve building, emphasizing the long-term value of the $6B revenue stream.
Molina Healthcare presents a classic 'value trap' versus 'turnaround opportunity' dilemma. The 2025 earnings collapse was severe, driven by a perfect storm of post-pandemic utilization acuity and regulatory surprises in California. The 2026 guidance of $5 EPS represents a massive step down, signaling that the 'trough' may be deeper and longer than initially hoped. However, the underlying narrative remains compelling: Molina maintains a dominant position in Medicaid with industry-leading margins (relative to peers) and has secured significant future revenue through the Florida CMS win and other RFP successes, totaling over $11 in embedded earnings. The decision to exit the volatile MAPD and Marketplace segments simplifies the business and reduces risk, positioning the company purely as a Medicaid/Duals specialist. For investors, the stock is a play on the 'rate restoration cycle.' If management is correct that 2026 is the bottom and actuarial soundness prevails, the current valuation offers a deep discount to the company's intrinsic earnings power of $15-$20 per share. However, given the history of guidance misses and the persistent inflation in medical costs, caution is warranted until the promised trend moderation materializes in the first half of 2026.
Management indicated that the Medicaid market is currently underfunded by 300 to 400 basis points based on stat filings. They believe this is unsustainable and that 'actuarial soundness will ultimately prevail,' forcing states to restore rates to cover the 5% medical cost trend.
Pharmacy trend remains high at 13%, with top 10 therapeutic classes trending at 36%. However, management noted that states are reintroducing utilization controls, such as requiring diabetes diagnoses for GLP-1 prescriptions (weight loss), which may help moderate future costs.
The 'redetermination' process has caused a 20% decline in industry membership since the pandemic ended. Molina notes that the 'low and no users' have largely been purged from the rolls, leaving a higher acuity mix that contributed to the 7.5% trend in 2025.
Professional office visits are trending at 16%, driven not just by volume but by 'service intensity'—specifically, an increase in the number of procedures (CPT codes) billed per visit (e.g., Level 3 becoming Level 4).